Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

News · September 17, 2018

HFSA 2018: Underuse of Angiotensin Receptor-Neprilysin Inhibitors for Heart Failure Is Not Due to Financial Barriers

Factors related to finances/insurance do not account for most underutilization of angiotensin receptor-neprilysin inhibition.

PracticeUpdate Editorial Team

 

Further Reading